23 Jul, 2026
According to Straits Research the global NGS sample preparation market size was valued at $2.71 billion in 2025 and is projected to grow from $3.08 billion in 2026 to $8.52 billion by 2034, at a CAGR of 13.58% during the forecast period 2026–2034.
The next-generation sequencing (NGS) industry is growing because of technologies that verify high-quality gene libraries and sequencing yields.
NGS changed how scientists study genes. NGS can take a day to sequence the human genome. The speed and flexibility of NGS are good for R&D. Sequencing advances are changing sample preparation techniques. Preparing the library and enriching the targets leads to correct sequencing and good data. Standard techniques for preparing samples have helped the NGS sample preparation industry grow because the field is always getting better. NGS is used to diagnose genetic diseases and treat them.
Diagnostics should rise rapidly within the foreseeable timeframe. Each cancer patient's genome is sequenced utilising quicker and cheaper NGS-based genomic sequencing. NGS can currently be employed in clinical practice and research. ESMO has three levels of NGS guidelines for August 2020. ESMO endorses routine use of NGS on advanced non-squamous non-small-cell lung cancer (NSCLC), cholangiocarcinoma, and ovarian, and prostate cancer tissues. For colon malignancies, NGS can replace PCR. NGS can uncover several genes and mutations by sequencing millions of DNA reads, which can help with therapy.
Global genomic research programmes are also propelling the NGS sample preparation industry. Genomic research can help us understand biology, human history, and health variations, as well as clinical ramifications. Recent developments in sequencing technology allow for therapeutically meaningful genome and exome testing. NGS helps diagnose and monitor infectious disorders, which may boost the industry.
NGS makes mutations with unclear clinical relevance more likely. Large numbers of genes may lead to unwanted results, such as illness risk factors or unclassifiable variations. Experts like molecular pathologists and clinical geneticists are needed to determine how hazardous the variations are. NGS and genetically overlapping disorders raise important challenges in patient care and follow-up. "Genetic purgatory" is what Ackerman calls a "variant of unknown significance" (VUS).
In its report "Globocan 2020," the International Agency for Research on Cancer (IARC) said that there would be 19.3 million new cancer cases and 10 million cancer deaths around the world in 2020. IARC says that 1 in 5 people will get cancer at some point in their lives, and 1 in 8 men and 1 in 11 women will die from the disease. Since the number of people with cancer is going up, there needs to be a lot more tools that can be used to make accurate diagnoses.
The market is split by region into North America, Europe, Asia-Pacific, and LAMEA.
In the global NGS sample preparation market, North America is where most of the money is made. The large share of this regional segment can be mostly attributed to government and private organisations' efforts to develop and use NGS technologies, the widespread use of NGS diagnostics in the region, the growing number of NGS-based research and clinical applications in the region, the growing research on cancer, the growing awareness of NGS services, and the presence of leading NGS service providers.
sales@straitsresearch.com